Importantly, the top predicted drug candidates are associated with distinct MOAs, including HMGCR inhibitors, i.e., statins and vitamin D receptor agonists, frequently across microarray and RNAseq TB datasets (Table 2 and Section 3.5). The gene discussed is HMGCR; the disease is tuberculosis.